
CAS 2130958-55-1
:Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
5 produits concernés.
N-[2-[[2-(Dimethylamino)ethyl]methylamino]-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]-2-propenamide methanesulfonate
CAS :Formule :C29H35F3N8O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :664.6990N-(2-((2-(Dimethylamino)Ethyl)(Methyl)Amino)-5-((4-(1-Methyl-1H-Indol-3-Yl)Pyrimidin-2-Yl)Amino)-6-(2,2,2-Trifluoroethoxy)Pyridin-3-Yl)Acrylamide Methanesulfonate
CAS :N-(2-((2-(Dimethylamino)Ethyl)(Methyl)Amino)-5-((4-(1-Methyl-1H-Indol-3-Yl)Pyrimidin-2-Yl)Amino)-6-(2,2,2-Trifluoroethoxy)Pyridin-3-Yl)Acrylamide MethanesulfonateDegré de pureté :99%Masse moléculaire :664.7g/molAlflutinib mesylate
CAS :Alflutinib mesylate (AST2818 mesylate) ,is an irreversible tyrosine kinase inhibitor that selectively inhibits EGFR mutations, especially T790M.Formule :C29H35F3N8O5SDegré de pureté :97.94% - 99.63%Couleur et forme :SolidMasse moléculaire :664.7Ast2818 mesylate
CAS :<p>Ast2818 mesylate is a small-molecule, orally active, selective factor receptor tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) and its downstream signaling proteins. Ast2818 mesylate binds to the EGFR at a site distinct from the ATP binding site and prevents phosphorylation by protein tyrosine kinases. It inhibits cell proliferation by blocking the activation of downstream signaling proteins such as Ras, Raf, and Akt. The compound has been evaluated in preclinical studies for potential use as an antineoplastic agent in lung cancer. In these studies, Ast2818 mesylate inhibited tumor growth in mouse models of lung cancer. Further analysis showed that this effect was due to inhibition of epidermal growth factor receptor-mediated signaling pathways involved in cell proliferation and tumorigenesis.</p>Formule :C29H35F3N8O5SDegré de pureté :Min. 95%Masse moléculaire :664.7 g/mol



